Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.41 |
| ▸ | CTSK | P43235 | 4/20 | 0.41 |
| ▸ | CTSL | P07711 | 4/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4770644 | 0.76 | CTSS (0.43) | CTSSCTSKCTSLPDGFRBFGFR1 | |
| SCHEMBL14004183 | 0.74 | CTSS (0.41) | CTSSCTSKCTSLPDGFRBFGFR1 | |
| SCHEMBL1981355 | 0.72 | PLK2 (0.52) | FGFR1ALDH1A1 | |
| SCHEMBL4833267 | 0.70 | CCND1 (0.53) | CTSSCTSKFGFR1 | |
| SCHEMBL4776155 | 0.70 | FGFR1 (0.53) | CTSSCTSKFGFR1 | |
| SCHEMBL13553948 | 0.69 | FGFR1 (0.36) | PDGFRBFGFR1ABL1ALDH1A1 | |
| SCHEMBL520644 | 0.69 | TSHR (0.31) | LTB4R | |
| SCHEMBL13859363 | 0.68 | LCK (0.54) | FGFR1ABL1 | |
| SCHEMBL2734374 | 0.68 | CDK4 (0.49) | FGFR1ALDH1A1 | |
| SCHEMBL22860654 | 0.68 | HSD17B10 (0.43) | CTSSCTSKCTSLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449472-B2 | Methods of inhibiting p38 with substituted bicyclic pyrimidines | ROCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449472-B2 | Methods of inhibiting p38 with substituted bicyclic pyrimidines | ROCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449472-B2 | Methods of inhibiting p38 with substituted bicyclic pyrimidines | ROCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-7439247-B2 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | ROCHE PALO ALTOP LLC (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439247-B2 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | ROCHE PALO ALTOP LLC (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439247-B2 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | ROCHE PALO ALTOP LLC (US) | 2008-10-21 | — | — | US | disclosed |
| EP-1485390-B1 | BICYCLIC PYRIDINE AND PYRIMIDINE P38 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | EP | disclosed |
| EP-1485390-B1 | BICYCLIC PYRIDINE AND PYRIMIDINE P38 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | EP | disclosed |
| CN-100386328-C | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2008-05-07 | — | — | CN | disclosed |
| US-7091347-B2 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060084803-A1 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | CHEN JIAN J | 2006-04-20 | — | — | US | disclosed |
| US-20050288312-A1 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | CHEN JIAN J | 2005-12-29 | — | — | US | disclosed |
| CN-1639168-A | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2005-07-13 | — | — | CN | disclosed |
| US-20030207900-A1 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | ROCHE PALO ALTO LLC | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288312-A1 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | MAPK1, MAP3K1, MAP3K8 | CTSS 4393/4885CTSK 2659/4885CTSL 3940/4885 |
| US-20030207900-A1 | Bicyclic pyridine and pyrimidine p38 kinase inhibitors | MAPK1, MAP3K1, MAPKAPK2 | CTSS 4461/4885CTSK 2785/4885CTSL 4193/4885 |
| US-20060084803-A1 | Bicyclic pyridine and pyrimidine P38 kinase inhibitors | MAPK1, MAP3K1, MAP3K8 | CTSS 4393/4885CTSK 2659/4885CTSL 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.